Results from JUNCTURE also showed the efficacy of secukinumab
300mg and 150mg based on a statistically significant higher
proportion of patients who achieved a PASI 75 response at
Week 12 compared with placebo: 86.7% (300mg) and 71.7%
(150mg), versus 3.3% for placebo (P<.0001). On the co-primary
endpoint, the efficacy of secukinumab 300mg and 150mg was
shown based on a statistically significant higher proportion of
patients who achieved an IGA mod 2011 0/1 response at Week
12 compared with placebo: 73.3% (300mg) and 53.3% (150mg),
versus 0% placebo (P<.0001).
Additionally, more secukinumab patients in both studies experienced
an improvement in PASI of greater than or equal to 90%
(PASI 90) from baseline as compared to placebo, which is a higher
standard of skin clearance compared to PASI 75. In FEATURE
60.3% (300mg) and 45.8% (150mg) of secukinumab patients
achieved a PASI 90 response at Week 12 compared to 0% of placebo
patients (P<.0001). In JUNCTURE, 55% (300mg) and 40%
(150mg) of secukinumab patients achieved a PASI 90 response at
Week 12 compared to 0% of placebo patients (P<.0001).
In FEATURE (n=177), the most common adverse events (AEs) in
any treatment group including placebo were diarrhea, nasopharyngitis
and headache. There were a total of four serious adverse
events in the study – three (5.1%) in the 300mg secukinumab
arm and one (1.7%) in the placebo arm. Two patients (one in
secukinumab 300mg arm, one in placebo arm) discontinued
due to AEs. In JUNCTURE (n=182), the most common AEs in
any treatment group including placebo were nasopharyngitis,
headache, pruritus and hypertension. There were a total of five
serious adverse events in the study – one (1.7%) in the 300mg
secukinumab arm, three (4.9%) in the 150mg secukinumab arm
and one (1.6%) in the placebo arm. One patient in the placebo
arm discontinued due to adverse event.
A secondary endpoint of both FEATURE and JUNCTURE measured
patient satisfaction and usability with self-injection of
secukinumab via PFS and AI, respectively. Satisfaction was assessed
in both studies using a self-administered Self-Injection
Assessment Questionnaire (SIAQ) which measures overall
subject experience with subcutaneous self-injection before the
first self-injection and after dosing on the domains of feelings
about injections, self-confidence, satisfaction with self-injection,
injection-site reactions, ease of use, and self-image. Overall, patient-
reported acceptability of both the PFS and AI were high at
baseline across both studies and remained high during the study.
These studies were presented in separate posters at AAD.
Studies presented at AAD are part of a clinical program reporting
results in moderate-to-severe plaque psoriasis with more
than 3,000 patients in over 35 countries.
FEATURE is a randomized double-blind, placebo-controlled,
multicenter, Phase III study involving 177 subjects with moderate-
to-severe plaque psoriasis. In this study, prefilled syringes
(PFS) were introduced into the secukinumab clinical program.
The co-primary endpoints were assessed at Week 12 and
compared secukinumab efficacy versus placebo according to
PASI 75 and Investigator's Global Assessment modified 2011
(IGA mod 2011) 0/1 response. Secondary endpoints included
PASI 90 response up to Week 12 and patient satisfaction with
self-injection of secukinumab via PFS determined by a self administered
Self-Injection Assessment Questionnaire (SIAQ).
The trial is ongoing.
JUNCTURE is a double-blind, placebo-controlled, multicenter,
Phase III study involving 182 subjects with moderate-to-severe
plaque psoriasis. In this study, the autoinjector/pen (AI)
was introduced into the secukinumab clinical program. The
co-primary endpoints were PASI 75 and Investigator's Global
Assessment modified 2011 (IGA mod 2011) 0/1 response for
secukinumab vs placebo at Week 12. Secondary endpoints
included PASI 90 response up to Week 12 and patient satisfaction
with self-injection of secukinumab via the AI device
determined by a self-administered Self-Injection Assessment
Questionnaire (SIAQ). The trial is ongoing.
FDA Approves Xolair
Genentech has announced that the FDA approved Xolair ®
(omalizumab) for the treatment of chronic idiopathic urticaria
(CIU), a form of chronic hives. The new use is for people
12 years of age and older who remain symptomatic despite
treatment with H1-antihistamine therapy5. Until now, H1-antihistamines
have been the only approved therapy for CIU, with
about 50 percent of patients having an inadequate response.
CIU is diagnosed when hives occur without an identifiable
cause, spontaneously present, and reoccur for more than six
weeks. CIU can have burdensome symptoms including swelling,
severe itch, pain, and discomfort that may last for many
months and even years. Approximately 1.5 million people in
the U.S. develop CIU at some stage in their life. Women are
twice as likely as men to experience CIU and most develop
symptoms between the ages of 20 and 40.
Xolair is the first biologic medicine and first medicine approved
by the FDA for CIU since non-sedating H1-antihistamines. Xolair
is approved for people 12 years and older with CIU who remain
symptomatic despite treatment with H1-antihistamine therapy.
Xolair is not used to treat other forms of urticaria (hives) and
is not for use in children less than 12 years of age. It is jointly
developed by Genentech and Novartis Pharma AG and is co-promoted
in the U.S. with Novartis Pharmaceuticals Corporation.
The efficacy and safety profile of Xolair for the treatment of CIU
was evaluated in two clinical studies called ASTERIA I and ASTERIA
II. In these studies, patients 12 to 75 years old received
doses of Xolair at 150 mg, 300 mg or placebo. Xolair or placebo